Clinical Trials Logo
  1. Home
  2. Carcinoid Tumor
  3. NCT00328497

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

Carcinoid Tumor Clinical Trial

Official title:
A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors

Clinical Trial Summary

This single center, open-label study will evaluate the safety and efficacy of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Dispersion (NCD) administered orally with recombinant human monoclonal antibody against vascular endothelial growth factor (bevacizumab) administered intravenously, in patients with locally advanced or metastatic carcinoid tumors.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00328497
Study type Interventional
Source CASI Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date May 2006
Completion date December 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT04993261 - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors Early Phase 1
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Active, not recruiting NCT03375320 - Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase 3
Completed NCT01435122 - A Study of Axitinib in Advanced Carcinoid Tumors Phase 2
Not yet recruiting NCT04039516 - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Phase 2
Completed NCT00780663 - Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Phase 2
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Completed NCT03723499 - Endoscopic Treatment of Bronchial Carcinoid Tumors
Recruiting NCT04017104 - Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT02399215 - Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Phase 2
Terminated NCT03420521 - Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Phase 2
Active, not recruiting NCT05477576 - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3
Not yet recruiting NCT02038738 - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00446082 - Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Phase 1
Active, not recruiting NCT05361668 - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Phase 2
Completed NCT01466036 - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase 2
Completed NCT01398306 - Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.